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Neointima hyperplasiaVascular smooth muscle cell (VSMC) proliferation plays a key role in neointimal hyperplasia and
restenosis. Here we report the role of the microRNA miR-142-5p and its downstream target genes
on the proliferation of cultured VSMCs. miR-142-5p promoted VSMC proliferation by down-regulat-
ing B cell translocation gene 3 (BTG3). We found that BTG3 inhibited the expression of cell cycle reg-
ulatory genes and cell growth. As shown by luciferase reporter assay, miR-142-5p bound directly to
the 30-untranslated region of BTG3. Overexpression of miR-142-5p induced expression of cell cycle
regulatory genes. Thus, BTG3, a novel, direct target of miR-142-5p, negatively regulates VSMC
proliferation.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Proliferation of vascular smooth muscle cells (VSMCs) contrib-
utes to in-stent restenosis, neointimal hyperplasia after stenting,
and angioplasty and vein bypass graft failure. In response to vascu-
lar injury, VSMCs release various growth mediators, including
PDGF, FGF-2, EGF, IGF-1, TGFb, and angiotensin II [1,2]. These
growth factors initiate VSMC proliferation. Therefore, anti-prolifer-
ative drugs have generated interest as a therapeutic strategy. A re-
cent area of focus in pathological vascular diseases is inhibition of
the cell cycle to inhibit or block VSMC proliferation.
Cyclins and cyclin-dependent kinases (CDKs) act as regulatory
molecules in the cell cycle. Inhibitors of CDK prevent cell cycle pro-
gression and are known tumor suppressors. The tumor suppressor
p53 is well known to have an anticancer effect and to inducegrowth arrest. Recently, Ou et al. reported that the tumor suppres-
sor B cell translocation gene 3 (BTG3) is a target of p53 and regu-
lates cell proliferation [3]. BTG3 has also been shown to be down-
regulated in renal cancer [4].
MicroRNAs (miRNAs) have recently been recognized as key reg-
ulators of gene expression in cell processes such as proliferation,
differentiation, apoptosis, development, and carcinogenesis [5–8].
miRNAs are small, non-coding, single-stranded RNAs of approxi-
mately 22 nucleotides that can serve as transcription factors owing
to their regulation of post-transcriptional gene expression. miRNAs
control gene expression through complementary binding to the 30-
untranslated region (UTR) of target mRNAs or by translational
repression. Dysregulation of miRNAs may be associated with vari-
ous diseases, including leukemia, cancers, diabetes, and heart dis-
ease [9–11]. Increasing evidence suggests that miRNAs play
important roles in proliferation-related diseases. For example,
miR-26 [12], miR-133 [13], miR-143 [14], miR-145 [15], and
miR-195 [16] are involved in VSMC phenotype and neointima for-
mation. Several reports have shown that miR-21[17], miR-130a
[18], and miR-146a [19] promote VSMC proliferation by down-reg-
ulating PTEN, GAX, and KLF4, respectively. Furthermore, the
expression of miR-221 and miR-222 is up-regulated in several hu-
man tumors as well as in proliferative VSMCs [20].
2386 H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392Bentwich et al. [21] reported that more than 800 miRNAs may
exist in humans. miRNAs are predicted to regulate one-third of hu-
man protein-coding genes [22]; however, the target functions of
only a few miRNAs have been evaluated.
In the present study, we aimed to identify the miRNAs that reg-
ulate VSMC proliferation in response to carotid injury. We also
characterized the downstream targets regulated by these prolifer-
ation-associated miRNAs in VSMCs and in a rat carotid artery bal-
loon injury model.
2. Materials and methods
2.1. Reagents, mimic miR-142-5p, siRNA BTG3, and antibodies
Human recombinant PDGF-BB was purchased from Sigma. Gap-
dh (sc-32233), cyclin E (sc-481), E2F3 (sc-878), and BTG3 (sc-
18545) were purchased from Santa Cruz. Cyclin D1 and cyclin D3
were purchased from Cell Signaling (#9932). MiRNA-142-5p, miR-
NA control, siRNA BTG3, and siRNA control were purchased from
Bioneer Company (South Korea).
2.2. Rat carotid injury model and microRNA array
The animal studywas approvedby the Ethics Committee of Chon-
nam National University Medical School. Male Sprague–Dawley rats1d 7d 14d
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Fig. 1. Expression of miR-142-5p and cell cycle-related genes in injured carotid arteries
142-5p in arteries with or without carotid balloon injury. The mRNA level of cyclin D1 (B
three pooled carotid arteries. (E) VSMCs were stimulated with PDGF-BB for the indicated
(F) Expression of miR-142-5p was determined in VSMCs stimulated with 10% FBS.weighing 180 to 200 g were used. The carotid injury model was pre-
pared as described previously [23]. For the miRNA array, total RNA
was isolated from artery tissue 10 days after injury. RNA quality
was determined by use of Agilent’s 2100 Bioanalyzer System. The
Agilent ratmiRNAmicroarray systemwas used to generate themiR-
NA expression proﬁle (GenomicTree Inc, South Korea).
2.3. Cell cultures
VSMCs were isolated from the aortic media of male rats by an
enzymatic dissociation method as described previously [23]. A10
cells were obtained fromAmerican Type Culture Collection (Manas-
sas, VA, USA). VSMCs and A10 cells were maintained in Dulbecco’s
modiﬁed Eagle’s medium containing 10% fetal bovine serum (FBS).
2.4. Plasmid construction
p3⁄Flag-CMV 10-rat BTG3 was prepared by subcloning after PCR
ampliﬁcation of the coding region of rat BTG3. The plasmid was
conﬁrmed by sequencing.
2.5. Luciferase reporter assay and site-directed mutagenesis
The detailed protocols are described in the online Supplemental
data. 
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and proliferative VSMCs. (A) Quantitative real-time PCR (qRT-PCR) analysis of miR-
), cyclin E (C), and E2F3 (D) was measured. In A–D, the mRNA level is the mean from
times. Expression of miR-142-5p normalized to 18S RNA was examined by qRT-PCR.
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For knockdown of BTG3 expression, BTG3 siRNA (50 or 100 nM)
was transfected with RNAi Max reagent according to the manufac-
turer’s instructions. A non-targeting siRNA was used as a control.
2.7. Cell proliferation assays and immunohistochemistry
Cell proliferation was determined by direct cell counting, MTT
assay, [3H]thymidine incorporation assay, and bromodeoxyuridineA 
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Fig. 2. miR-142-5p increases proliferation and DNA synthesis in VSMCs. (A) Two days aft
cell counting of VSMCs. The left panel indicates transfection with 25 nM miR-142-5p, wh
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Detailed protocols are described in the online Supplemental
data.
2.8. miRNA target analysis
To identify predicted targets of miR-142-5p, we used the miR-
Base Target database and the microRNA target prediction program
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Fig. 3. miR-142-5p regulates cell cycle-related genes in VSMCs. (A) VSMCs were
transfected either control (25 nM) or miR-142-5p mimic. Two days after transfec-
tion, the protein expression of cyclin D1, cyclin D3, E2F3, and cyclin E was
determined by Western blot analysis. (B–E) Quantiﬁcation of cyclin D1, cyclin D3,
E2F3, and cyclin E, respectively, from three different sets of Western blots.
2388 H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392evaluated by real-time reverse transcription-polymerase chain
reaction (RT-PCR).
2.9. Real-time reverse transcription-polymerase chain reaction and
Western blot analysis
Protocols for RT-PCR and Western blot are described in the on-
line Supplemental data.
2.10. Statistical analysis
Statistical analysis was performed with either Student’s t-test
or one-way ANOVA with a Bonferroni post hoc test with software
provided by GraphPad Prism version 5. Data are presented as
means ± S.E.M. P values of <0.05 were considered statistically
signiﬁcant.
3. Results
3.1. miR-142-5p expression is induced in response to rat carotid injury
and in cultured proliferative VSMCs
We performed a miRNA array to identify the miRNAs involved
in neointimal hyperplasia after carotid injury. Of the upregulated
miRNAs that showed changes over twofold, we selected miR-
142-5p, which increased ﬁvefold. We then examined the expres-
sion of miR-142-5p over the time course of carotid injury. As
shown Fig. 1A, miR-142-5p expression was induced sevenfold very
early (1 day) after carotid injury compared with the uninjured
group (sham) and then gradually decreased. We further investi-
gated changes in other genes involved in cell cycle regulation dur-
ing carotid balloon injury. As shown in Fig. 1B, the cyclin D1 level
was increased at 1 day after artery injury and peaked at 7 days.
Expression of cyclin E, another key regulator of G1/S phase transi-
tion, was dramatically increased at 1 day and then gradually de-
creased (Fig. 1C). E2F3 expression was higher in the injury group
than in the uninjured group (Fig. 1D). To further investigate the
expression of miR-142-5p in proliferating VSMCs, cells were stim-
ulated with PDGF-BB or FBS. miR-142-5p was time-dependently
higher in stimulated VSMCs than in unstimulated cells (Fig. 1E
and F).
3.2. miR-142-5p promotes VSMC proliferation in VSMCs
We next transfected miR-142-5p mimic or miR control into
VSMCs and evaluated cell proliferation by direct cell counting
and MTT assay. As shown Fig. 2A and B, cell numbers were in-
creased in cells transfected with 25 or 50 nM miR-142-5p mimic
compared with the control. The same result was shown by use of
the MTT assay. To further determine whether the proliferation in-
duced by miR-142-5p was linked to DNA synthesis, we performed
a [3H]thymidine incorporation assay in VSMCs. As shown in Fig. 2C,
miR-142-5p signiﬁcantly increased the DNA synthesis in VSMCs. In
addition, the proliferative activity of miR-142-5p was evaluated by
BrdU incorporation. Increased BrdU uptake was shown in the cells
transfected with the miR-142-5p mimic (Fig. 2D).
3.3. miR-142-5p regulates cell cycle genes in VSMCs
Cell cycle arrest or cell cycle proliferation genes are involved in
the neointimal hyperplasia during VSMC proliferation. To conﬁrm
whether miR-142-5p affected cell cycle-related genes, we per-
formed Western blot. As shown in Fig. 3, we found that the protein
level of cyclin D1 and cyclin D3, G1/S-speciﬁc cyclin D, was in-
creased by miR-142-5p mimic. The expression of cyclin E and thatof the cell cycle control protein E2F3 was also increased in VSMCs
transfected with miR-142-5p.
3.4. miR-142-5p decreases BTG3 expression in VSMCs
We next used bioinformatics tools to identify candidate target
genes of miR-142-5p. Considering the pro-proliferative role of
miR-142-5p on VSMCs, we hypothesized that the downstream tar-
get genes would be associated with cell cycle arrest. Therefore, we
ﬁrst evaluated whether miR-142-5p down-regulated the expres-
sion of the predicted target genes. We selected ﬁve candidate
genes: BTG3, DLG1, GAS7, KLF10, and KLF11. We conﬁrmed that
miR-142-5p expression was induced by transfection of miR-142-
5pmimic into VSMCs (Fig. 4A). Of the genes examined, BTG3mRNA
and protein expression was decreased in miR-142-5p mimic-trans-
fected VSMCs (Fig. 4B and C). Furthermore, the BTG3 mRNA level
was up-regulated reciprocally with miR-142-5p in the carotid ar-
tery injury model (Fig. 4D). To further conﬁrm the levels of BTG3
protein, we performed immunohistochemistry using BTG3 anti-
body. As shown in Fig. 4E, BTG3 protein expression was increased
in the neointima of injured tissue compared with uninjured tissue.
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H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392 2389Next, we determined whether overexpression of miR-142-5p could
speciﬁcally act on the expression of miR-142-5p. As shown in
Fig. 4F, miR-142-5p mimic increased the expression of miR-142-
5p but miR-503 mimic did not affect the expression of miR-142-
5p. To further determine whether miR-142-5p could directly bind
to BTG3, we generated a luciferase construct with and without
the putative miR-142-5p sequence. We found that miR-142-5p
inhibited BTG3 30-UTR luciferase activity, whereas miR-142-5pfailed to inhibit luciferase activity with the mutated luciferase con-
struct (Fig. 4H). These results suggested that BTG3 is a candidate
target gene of miR-142-5p in VSMCs.
3.5. BTG3 inhibits VSMC proliferation and cell cycle genes
Because the BTG family, a family of tumor suppressor genes, has
been implicated in the regulation of cell cycle progression [24], we
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Fig. 5. BTG3 suppresses the proliferation of VSMCs. (A and B) After transfection with vector or p3⁄Flag-CMV10-BTG3 plasmid construct, cell proliferation and DNA synthesis
were determined by direct cell counting and [3H]thymidine incorporation in A10 cells. (C) MTT assay in BTG3-transfected A10 cells in the presence or absence of PDGF-BB. (D)
Thymidine incorporation in VSMCs transfected with BTG3 in the presence or absence of PDGF-BB. (E) The effect of BTG3 on miR-142-5p-induced cell proliferation. (F) Protein
expression of cell cycle-related genes was determined by Western blot analysis. (G and H). Quantiﬁcation of E2F3 and cyclin D3 protein expression from the results of the
immunoblot analysis.
2390 H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392characterized the effect of BTG3 in A10 cells. Because it is difﬁcult
to use primary cultured VSMCs for gene transfection, we used A10
cells for overexpression of BTG3. As shown in Fig. 5A, BTG3 showed
an anti-proliferative effect as determined by cell counting. Further-
more, as shown in Fig. 5B, BTG3 decreased thymidine uptake in
VSMCs. BTG3 also signiﬁcantly suppressed PDGF-BB-stimulated
VSMC proliferation (Fig. 5C). Consistent with the result from direct
cell counting, BTG3 inhibited DNA synthesis induced by PDGF-BB
treatment in VSMCs (Fig. 5D). To further identify the effect of
BTG3 on miR-142-5p-induced proliferation, direct cell counting
was conducted by co-transfection of miR-142-5p and BTG3 inVSMCs. We found that BTG3 completely inhibited the cell prolifer-
ation induced by miR-142-5p (Fig. 5E).
We then determined the effect of BTG3 on the expression of cell
cycle control genes. As expected, the expression of E2F3 and cyclin
D3 was decreased in the BTG3-overexpressed VSMCs compared
with the expression in untransfected VSMCs (Fig. 5F-H).
3.6. siBTG3 promotes VSMC proliferation and DNA synthesis
To further demonstrate the role of BTG3 in cell proliferation, we
performed a gene knockdown experiment. We conﬁrmed reduced
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5p/BTG3/cell cycle gene pathway in VSMC proliferation. miR-142-5p expression is induced in PDGF-BB-stimulated VSMCs or rat carotid injury. miR-142-5p inhibits BTG3
expression.
H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392 2391mRNA and protein expression of BTG3 by transfecting A10 cells
with siRNA against BTG3 (Fig. 6A). We found that siBTG3 at a con-
centration of 10 or 50 nM increased VSMC proliferation (Fig. 6B).
Consistent with the results for cell growth, the DNA synthesis rate
was increased with BTG3 knockdown (Fig. 6C). Next, we investi-
gated whether down-regulation of BTG3 affected PDGF-BB-stimu-
lated cell proliferation and DNA synthesis. As shown in Fig. 6D and
E, the increased cell proliferation and DNA synthesis induced by
PDGF-BB treatment were further enhanced by siRNA BTG3 com-
pared with the siRNA control.
4. Discussion
The results of the present study showed that miR-142-5p ex-
pressed in proliferative VSMCs and in a rat carotid artery injury
model regulates cell proliferation and the expression of cell cyclecontrol genes. As shown in Fig. 6F, PDGF-BB/miR-142-5p/BTG3/cy-
clin D3 signaling is a novel pathway in the modulation of VSMC
proliferation.
We discovered some of the miRNAs involved in VSMC prolifer-
ation by use of miRNA array. Of these identiﬁed miRNAs, we found
that miR-142-5p was strongly induced at an early time point after
rat carotid balloon injury. By contrast, miR-142-5p expression was
not increased at the late time point after carotid injury. Cell cycle
regulatory genes, including cyclin D1, cyclin E, and E2F3, were
enhanced in the carotid artery injury model. We conﬁrmed that
miR-142-5p is highly expressed in VSMCs stimulated with FBS or
PDGF-BB, and we showed that miR-142-5p increases VSMC prolif-
eration and DNA synthesis. Furthermore, overexpression of miR-
142-5p up-regulated cell cycle control genes, such as cyclin D1,
cyclin D3, E2F3, and cyclin E. Our results thus indicate that miR-
142-5p is a pro-proliferative miRNA in VSMCs.
2392 H.J. Kee et al. / FEBS Letters 587 (2013) 2385–2392Considering the pro-proliferative effect of miR-142-5p, we
hypothesized that miR-142-5p must down-regulate anti-prolifera-
tive genes. To search for the downstream target of miR-142-5p, we
used a microRNA target prediction program. In the preliminary
study, we examined the expression of BTG3, DLG1, GAS7, KLF10,
and KLF11 by qRT-PCR. It was recently reported that miR-142-5p
plays a critical role in the pathogenesis of gastric mucosa-associ-
ated lymphoid tissue lymphoma [25] and is a predictor for recur-
rence risk in gastric cancer patients [26].
The Rouault research group ﬁrst cloned mouse BTG3 and char-
acterized its role in the cell cycle [24]. Some evidence has shown
that BTG3 expression is down-regulated in various cancers [27].
We obtained evidence in the present study that BTG3 mRNA and
protein expression are down-regulated by miR-142-5p. Our result
in the truncated luciferase assay showed that miR-142-5p can bind
directly to the BTG3 30-UTR in VSMCs. Thus, the results of our study
indicate that BTG3 may be a candidate miR-142-5p target gene.
However, because miRNA can bind to the 30-UTR of multiple genes,
the pro-proliferative mechanism of miR-142-5p may be regulated
by other downstream targets in addition to BTG3.
By both gain-of-function and loss-of-function study, we found
that BTG3 inhibited cell proliferation in the presence or absence
of PDGF-BB treatment in VSMCs. BTG3 especially decreased the
expression of cyclin D3 in VSMCs. However, we found that BTG3
expression in injured artery was increasingly higher than that in
uninjured artery, whereas cell cycle control genes including cyclin
D1 and E2F3 were also increased at 2 weeks after carotid injury. In
other words, these ﬁndings imply that genes with pro-proliferative
and anti-proliferative effects act simultaneously on cell growth
during neointimal formation. Vernell et al. reported that BTG3 is
one of the target genes of E2Fs and that BTG3 expression is up-reg-
ulated by E2Fs [28]. That study supports our experiment results
with the expression of BTG3 and E2F3 in injured arteries.
In conclusion, we have shown that BTG3, a novel downstream
target of miR-142-5p, can negatively regulate VSMC cell growth
via suppression of cell cycle-related genes. We suggest that BTG3
may have therapeutic potential in cardiovascular diseases.
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